Search
for
Sort by
Research 301–330 of 1000+
- Phase I Clinical Testing Antimalarial Drugs.
- Application of 2-Chloro-7-Nitrobenzo-2-Oxa-1, 3-Diazol (NBDCL) for Spectrophotometric Determination of Finasteride in Pharmaceutical Formulation
- A Case Study of Androgenetic Alopecia in woman Improved by Pharmacopuncture Therapy and Needle-embedding Therapy
- Superior Root Hair Formation Confers Root Efficiency in Some, But Not All, Rice Genotypes upon P Deficiency
- <i>Bacillus subtilis</i> promotes plant phosphorus (P) acquisition through P solubilization and stimulation of root and root hair growth
- New effects of caffeine on corticotropin‐releasing hormone (CRH)‐induced stress along the intrafollicular classical hypothalamic–pituitary–adrenal (HPA) axis (CRH‐R1/2, IP<sub>3</sub>‐R, ACTH, MC‐R2) and the neurogenic non‐HPA axis (substance P, p75<sup>NTR</sup>and TrkA) in<i>ex vivo</i>human male androgenetic scalp hair follicles
- Substance P prolongs human hair growth in vitro
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
- Clinical Pharmacokinetics and Pharmacodynamics of Finasteride
- Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
- The mouse hairy ears mutation exhibits an extended growth (anagen) phase in hair follicles and altered <i>Hoxc</i> gene expression in the ears
- Nuclear factor (erythroid-derived 2)-like-2 pathway modulates substance P–induced human mast cell activation and degranulation in the hair follicle
- TRPV3 Ion Channel: From Gene to Pharmacology
- DSP c.6310delA p.(Thr2104Glnfs*12) associates with arrhythmogenic cardiomyopathy, increased trabeculation, curly hair, and palmoplantar keratoderma
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- A Scoping Review of Pharmacotherapy, Complementary, and Alternative Medicine (CAM), and Surgical Therapies for Androgenic Alopecia
- Evaluation of serum substance P,folic acid and ferritin in female patients with hair fall and trichodynia
- LB1017 A novel link between human hair follicle neuroimmunology and mitochondrial biology: Substance P increases intrafollicular oxidative stress and mitochondrial biogenesis
- 639-P: Pharmacological Mobilization and Recruitment of Bone Marrow Stem Cells Accelerates Diabetic Wound Healing in Rats with Diabetic Complications
- Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies
- Kevis P.F. – an adjunctive hair maintenance option
- Pilose antler extract promotes hair growth in androgenic alopecia mice by promoting the initial anagen phase
- A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia
- Hair Cycle Resting Phase Is Regulated by Cyclic Epithelial FGF18 Signaling
- The pharmacology of methotrexate
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- PDGF isoforms induce and maintain anagen phase of murine hair follicles
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- Chronic Restraint Stress Inhibits Hair Growth via Substance P Mediated by Reactive Oxygen Species in Mice
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)